<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39451031</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1550-6606</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of immunology (Baltimore, Md. : 1950)</Title><ISOAbbreviation>J Immunol</ISOAbbreviation></Journal><ArticleTitle>TP53 Codon 72 Polymorphism Impacts Macrophage Activation through Reactive Oxygen Species-Dependent Cell Signaling Alterations.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ji2400212</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.2400212</ELocationID><Abstract><AbstractText>The role of the most common TP53 single-nucleotide polymorphism (SNP) at codon 72, which encodes for proline (P72) or arginine (R72), in the regulation of the immune system has not yet been thoroughly explored. We found that this SNP contributes to aggravated inflammatory response in COVID-19 patients resulting from biased macrophage activation. R72-P53 inhibits mitochondrial manganese superoxide dismutase, leading to impaired reactive oxygen species scavenging, oxidation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and, consequently, its inhibition. Reduced PTEN activity causes constitutive activation of the PI3K/Akt pathway, which restricts proinflammatory (M1) and promotes anti-inflammatory (M2) phenotypes through NF-κB and p53 inhibition. In contrast, PTEN-reduced PI3K/Akt activity, in P72 carrying cells, favors M1 phenotypes. LPS-stimulated R72 macrophages fail to reduce tumor growth in a mouse model of cancer, in contrast with P72 macrophages, which preserve M1 phenotype in vivo and reduce tumor growth by enhancing antitumor T cell responses, consistent with antitumor functions of M1 macrophages. In addition, P72 macrophages contributed to increased mortality in a mouse model of LPS-induced endotoxemia. Therefore, given the high frequency of P72 in African Americans, cell signaling alterations driven by codon 72 of TP53 SNP may potentially contribute to differences in clinical outcomes and health disparities in common diseases associated with dysregulated macrophage activation.</AbstractText><CopyrightInformation>Copyright © 2024 by The American Association of Immunologists, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silwal</LastName><ForeName>Ashok</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5040-5725</Identifier><AffiliationInfo><Affiliation>Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reese</LastName><ForeName>Britney</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-7193-5995</Identifier><AffiliationInfo><Affiliation>Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Bhaumik</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-8304-8509</Identifier><AffiliationInfo><Affiliation>Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0009-5666-6892</Identifier><AffiliationInfo><Affiliation>Research, Apellis Pharmaceuticals Inc., Waltham, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolev</LastName><ForeName>Martin V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Discovery, Apellis Pharmaceuticals Inc., Waltham, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La-Beck</LastName><ForeName>Ninh M</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0002-1956-3263</Identifier><AffiliationInfo><Affiliation>Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy Practice, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karbowniczek</LastName><ForeName>Magdalena M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markiewski</LastName><ForeName>Maciej M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0002-8271-8918</Identifier><AffiliationInfo><Affiliation>Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CA190209</GrantID><Agency>HHS | NIH | National Cancer Institute (NCI)</Agency><Country /></Grant><Grant><GrantID>HL160972</GrantID><Agency>HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Immunol</MedlineTA><NlmUniqueID>2985117R</NlmUniqueID><ISSNLinking>0022-1767</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39451031</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.2400212</ArticleId><ArticleId IdType="pii">267272</ArticleId></ArticleIdList></PubmedData></PubmedArticle>